Physician profile
Rochele Spires
NPI 1740450113
$2,006.54
in general payments reported to CMS, 2019-2025
34 companies · $119 in 2025
The $119 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $625 · 2022: $591 · 2023: $488 · 2024: $184 · 2025: $119.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $791.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $790.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $301.11 | 2021-2023 | Tivdak |
| Merck Sharp & Dohme LLC | $163.97 | 2022-2025 | Keytruda, Lynparza |
| Bayer Healthcare Pharmaceuticals INC. | $139.80 | 2022-2023 | |
| Abbvie INC. | $135.85 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $133.93 | 2022 | |
| Janssen Biotech, INC. | $124.71 | 2021-2022 | |
| Ipsen Biopharmaceuticals, INC | $119.86 | 2021 | |
| Pfizer INC. | $74.65 | 2021 | |
| Pharmacyclics LLC, An Abbvie Company | $68.52 | 2021 | |
| Astellas Pharma US INC | $63.41 | 2023-2024 | Veozah |
| Davol INC. | $50.65 | 2023-2024 | Arista Ah Flexitip |
| Astrazeneca Pharmaceuticals LP | $50.30 | 2023-2025 | Lynparza |
| Eisai INC. | $48.87 | 2022-2024 | |
| Jazz Pharmaceuticals INC. | $46.33 | 2021-2025 | |
| Puma Biotechnology, INC. | $40.55 | 2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Global Blood Therapeutics, INC. | $40.14 | 2021-2022 | |
| Genzyme Corporation | $39.97 | 2021-2022 | |
| Genentech USA, INC. | $33.29 | 2022 | |
| Integra Lifesciences Corporation | $27.12 | 2024 | Tenoglide |
| Foundation Medicine, INC. | $24.97 | 2023 | Foundationone Liquid Cdx |
| Servier Pharmaceuticals LLC | $24.91 | 2025 | |
| Baxter Healthcare | $24.68 | 2023 | Tisseel |
| Boston Scientific Corporation | $24.44 | 2024 | Upsylon |
| Glaxosmithkline, LLC. | $24.21 | 2021 | |
| Immunogen, INC. | $21.44 | 2023 | Elahere |
| Lilly USA, LLC | $20.30 | 2022 | |
| Epizyme, INC. | $19.29 | 2021 | |
| Beigene USA, INC. | $19.25 | 2021 | |
| Recordati_rare_diseases_inc. | $19.21 | 2022 | |
| Eusa Pharma (US) LLC | $19.21 | 2022 | |
| Accord Healthcare, INC. | $17.63 | 2025 | |
| Deciphera Pharmaceuticals INC. | $15.92 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $14.15 | 2022 | |
| Array Biopharma INC | $13.90 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rochele Spires listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.